TrialSignal
Clinical trial intelligence report
A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT00996515-Jul 28, 2026
NCT ID
NCT00996515
Status
COMPLETED
Phase
PHASE1
Sponsor
New Mexico Cancer Research Alliance
Executive brief
Investment-Ready Snapshot
A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies is a PHASE1 clinical asset sponsored by New Mexico Cancer Research Alliance in Advanced Solid Tumor Malignancies. SEO and diligence focus: 5-azacytidine, erlotinib, Erlotinib PO and Vidaza IV, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00996515
Indication
Advanced Solid Tumor Malignancies
Modality
small molecule
Target
5-azacytidine, erlotinib, Erlotinib PO and Vidaza IV
Intervention
5-azacytidine, erlotinib, Erlotinib PO and Vidaza IV
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.